The DOI matches its Crossref record.
The USP8 mutational status may predict drug susceptibility in corticotroph adenomas of Cushing's disease
Abstract
Context: Somatic mutations in the ubiquitin-specific peptidase USP8 gene were recently detected in one- to two-third(s) of corticotroph adenomas of Cushing's disease (CD). These mutations may lead to the deubiquitination of EGFR, thereby increasing EGFR signaling, which has been implicated in ACTH hypersecretion. Objective: Our objective was to determine the impact of USP8 mutations on the clinicopathological features of CD. Subjects and methods: USP8 mutations as well as clinicopathological characteristics were examined in 60 corticotroph adenomas including 15 Crooke's cell adenomas (CCAs), a rare histological variant presenting with generally aggressive behavior, using qRT-PCR and/or immunohistochemistry. Results: USP8 mutations were exclusively detected in women, except for one case, with a prevalence of 42.2% in non-CCA and 13.3% in CCA (overall 35%). Clinically well-behaved presentations including microadenoma and curative resection were more common in mutated cases. The expression of EGFR was not associated with the mutation status. In contrast, mutated tumors expressed significantly higher levels of POMC , SSTR5, and MGMT. Conclusions: Microadenomas that strongly express POMC were common among mutated tumors, which may lead to the mechanisms by which very small adenomas secrete excess ACTH to present overt CD. While USP8 mutations were less likely to enhance tumorous ACTH hypersecretion via EGFR-mediated activation, the presence of USP8 mutations may predict favorable responses to the somatostatin analog pasireotide, which exhibits high affinity for SSTR5. In contrast, non-mutated aggressive tumors such as CCA may respond better to the alkylating agent temozolomide because of their significantly weak expression of MGMT.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Consensus on diagnosis and management of Cushing's disease: a guideline update
Fleseriu, M., Auchus, R., Bancos, I., Ben-Shlomo, A., Bertherat, J., Biermasz, N. R., Boguszewski, C. L., Bronstein, M. D., Buchfelder, M., Carmichael, J. D., et al. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00235-7 · Cited by 953
Overview of the 2017 WHO Classification of Pituitary Tumors
Mete, O., & Lopes, M. B. (2017) · Endocrine Pathology · doi:10.1007/s12022-017-9498-z · Cited by 460
Pangenomic Classification of Pituitary Neuroendocrine Tumors
Neou, M., Villa, C., Armignacco, R., Jouinot, A., Raffin-Sanson, M.-L., Septier, A., Letourneur, F., Diry, S., Diedisheim, M., Izac, B., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2019.11.002 · Cited by 340
Günther, T., Tulipano, G., Dournaud, P., Bousquet, C., Csaba, Z., Kreienkamp, H.-J., Lupp, A., Korbonits, M., Castaño, J. P., Wester, H.-J., et al. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.015388 · Cited by 253
Nishioka, H., & Yamada, S. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8111951 · Cited by 65
Self-citation
Metadata
- Authors
- Hayashi, K., Inoshita, N., Kawaguchi, K., Ibrahim Ardisasmita, A., Suzuki, H., Fukuhara, N., Okada, M., Nishioka, H., Takeuchi, Y., Komada, M., Takeshita, A., & Yamada, S.
- Venue
- European Journal of Endocrinology
- Publisher
- Oxford University Press (OUP)
- Published
- 2016-02
- Volume
- 174
- Issue
- 2
- Pages
- 213-226
- ISSN
- 0804-4643 (ISSN-L)
- 1479-683X
- OpenAlex
- W2252521414
- Cited by
- 162
- References
- 0
- FWCI
- 10.13
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The USP8 mutational status may predict drug susceptibility in corticotroph adenomas of Cushing's disease. https://app.cochat.ai/papers/10.1530/eje-15-0689
- The paper
- Hayashi, K., Inoshita, N., Kawaguchi, K., Ibrahim Ardisasmita, A., Suzuki, H., Fukuhara, N., Okada, M., Nishioka, H., Takeuchi, Y., Komada, M., Takeshita, A., & Yamada, S. (2016). The USP8 mutational status may predict drug susceptibility in corticotroph adenomas of Cushing's disease. European Journal of Endocrinology. https://doi.org/10.1530/eje-15-0689
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.